ImmunoBiochem raises funding from angels, founding investor
Canadian biopharmaceutical company ImmunoBiochem Corp has raised undisclosed financing. The round was backed by angel investors and the company’s founding investor, which were not identified. Located at Johnson & Johnson Innovation-JLABS in Toronto, ImmunoBiochem has developed technology that targets unique proteins in the secretomes of cancer cells with antibody-drug conjugates. It is completing pre-clinical development and plans to bring the new therapies into the clinic. Led by CEO Anton Neschadim, ImmunoBiochem is supported by MaRS Health and the H2i accelerator at the University of Toronto.
11 December 2017•6 mins read
